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TREATMENT PATTERNS AMONG NEWLY
DIAGNOSED CORONARY HEART DISEASE
PATIENTS: CORRELATES OF LIPID
MANAGEMENT
Watson-Heidari T1, Ershoff D2, Stacy J1, O’Donnell JC2,
Schmaltz S1, McDonough KL2, Sandman T1
1Humana Inc, Louisville, KY, USA; 2AstraZeneca LP, Wayne,
PA, USA
OBJECTIVES: In support of secondary prevention
efforts, NCEP guidelines have afﬁrmed the importance of
intensive management of LDL cholesterol in established
CHD patients. The objective of this retrospective, cohort
analysis was to examine correlates of “optimal” lipid
management among newly diagnosed CHD patients. 
The population was drawn from a health beneﬁts com-
pany under capitation (commercial, Medicare) and PPO
arrangements. METHODS: Eligible subjects (N =
10,125) had an index medical claim for CHD in Year
2000 (ICD-9 CM codes of 410–414, Procedure codes of:
36.0–36.3), no such diagnostic codes during a previous
24-month “clean” period, no pharmacy claims for a lipid-
lowering agent (LLA) in the six month period prior to the
index diagnosis, and continuous enrollment during the
36-month observation period. “Optimal” management
was deﬁned as at least 1 claim for a LLA in all four quar-
ters of a 12-month post-index follow-up period, coupled
with at least 1 lab claim associated with lipid monitoring
(lab values were not available for analysis). RESULTS:
Patients classiﬁed as receiving “optimal” management
equaled 4.9%, with 50.3% classiﬁed as receiving nei-
ther a lab claim nor a LLA. A logistic regression identi-
ﬁed ﬁve statistically signiﬁcant (P < 0.01) predictors of
“optimal” management, including: a) identiﬁcation by a
diagnosis of acute MI; b) age < 65 years; c) male gender;
d) a comorbidity of hypertension; and e) initial CHD
diagnosis by a physician other than a cardiologist/
cardiovascular surgeon. CONCLUSIONS: Effective lipid
management in patients with CHD has been linked to
reduced mortality, decreased morbidity and lower treat-
ment costs. Nonetheless, study ﬁndings identify a large
gap between the promise of pharmacotherapy and per-
formance in clinical practice. Increased promotion of
guidelines emphasizing the importance of aggressive lipid
management for both physicians and patients may be nec-
essary to decrease this gap and to achieve desired objec-
tives of secondary prevention of CHD.
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DISEASE MANAGEMENT REDUCES
HEALTHCARE DISPARITIES IN HEART 
FAILURE PATIENTS
Walker DR, Landis DL, O’Leary JS,Vance RP
CorSolutions, Buffalo Grove, IL, USA
OBJECTIVE: To provide evidence that a heart failure
(HF) disease management (DM) program can reduce dis-
parities in healthcare outcomes in minority populations.
METHODS: The study sample included HF patients who
were in a nurse-mediated DM program for at least 90
days, and who had a minimum of 2 quality of life (QOL)
and 2 NYHA measurements. QOL was measured for
both physical (PCS) and mental health (MCS) using the
SF-8 survey instrument. QOL and NYHA were measured
at the time of program enrollment and quarterly there-
after. Baseline QOL and NYHA scores were compared to
the most recent. The 95% conﬁdence interval for clinical
signiﬁcance is +/- 6.3 for MCS and +/- 5.7 for PCS. There
were 2578 patients in the sample, of which 2081 were
white and 497 were black. Blacks were signiﬁcantly
younger than whites (67 and 72 years of age), and were
more female (61% and 52%). RESULTS: The mean PCS
at baseline was 38.16 and 37.96, for whites and blacks
respectively. The mean PCS for the most recent scores was
41.39 (p < 0.0001) and 42.01 (p < 0.0001) respectively
for whites and blacks. Importantly, 39% and 45% of
whites and blacks had clinically signiﬁcant improvements
in PCS. The mean MCS at baseline was 46.44 and 47.28,
for whites and black respectively. The mean MCS for 
the most recent score was 47.84 (p < 0.0001) and 48.21
(p = 0.05) respectively for whites and blacks. Twenty
seven percent of both groups had clinically signiﬁcant
improvements in MCS. At baseline, 45% of whites and
only 35% of blacks were NYHA I or II. For the current
measurement 57% of whites and 59% of blacks were
NYHA I or II. CONCLUSIONS: Based upon these





A COST-BENEFIT MODEL FOR PERINDOPRIL IN
SECONDARY STROKE PREVENTION
Hartzema AG,Winterstein AG, Kwon SY
University of Florida, Gainesville, FL, USA
The PROGRESS trial demonstrated the effectiveness of
perindopril/indapamide in secondary stroke prevention
(SSP). No existing economic study has incorporated these
ﬁndings in a cost-beneﬁt analysis. OBJECTIVES: The
objective of this analysis was to evaluate the cost/beneﬁt
of perindopril/indapamide in SSP. METHODS: The
model used a decision tree approach to estimate direct
cost savings associated with SSP for a hypothetical cohort
of 10,000 ﬁrst stroke survivors from an HMO’s perspec-
tive (1 Mio covered lives) over a 3-year time period. Inci-
dence estimates for 2nd stroke and healthcare utilization
as well as pharmacoeconomic estimates are presented 
for each year and separated for the two major stroke
types (ischaemic and hemorrhagic stroke). First, stroke
incidence and transition probabilities for healthcare uti-
lization were abstracted from the published epidemio-
logic literature, incidence of second strokes from the
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PROGRESS trial. Cost for stroke-related hospitalization
and re-hospitalization, rehabilitation, nursing home, 
and ambulatory care derived from national data and 
published literature. Historical cost data was inﬂation-
adjusted to 2001 values, savings in the 2nd and 3rd year
were discounted at 3%, and health care CPI inﬂation-
adjusted at 4.7%. Treatment and control group (no SSP
medication) were replenished after the 1st and 2nd year
in equal numbers with newly SSP eligible patients (new
ﬁrst stroke survivors of the HMO population). Drug
prices were deﬁned as WAC-20% plus $5 co-pay. Sensi-
tivity analysis on stroke incidences, selected transition
probabilities and costs will be presented. RESULTS: SSP
with perindopril/indapamide saved 28 lives and 110
strokes in the ﬁrst year (after 3 years 169 and 325 respec-
tively). Treatment achieved a net beneﬁt of $803,000 in
the ﬁrst, $3,267,253 in the second and $6,207,814 by the
third year. The cost per stroke prevented was $24,648 and
$47,412 per death averted over the three year period.
CONCLUSIONS: SSP with perindopril/indapamid saves
lives and healthcare costs.
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RATES OF HOSPITALIZATIONS FOLLOWING
ATHEROTHROMBOTIC STROKE AND
ASSOCIATED COSTS
Caro J1, Migliaccio-Walle K1, Ishak K2, O’Brien JA1
1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Dorval, QC, Canada
OBJECTIVES: To estimate the rate of hospitalizations
due to cardiovascular disease and other causes following
an acute atherothrombotic stroke and the associated
costs. METHODS: We evaluated hospitalization rates
(cumulative number divided by the patient time in a given
period) following a diagnosis of acute stroke using the
health care records of residents of Saskatchewan, Canada
who were diagnosed between 1990–1995. Data on
patient characteristics and medical history were available
from January 1980 and follow-up was complete to
December 2000. Costs (2002 Canadian dollars) were also
estimated. Reasons for hospitalization were classiﬁed on
the basis of primary diagnosis, into atherothrombotic
(stroke, TIA, myocardial infarction, angina, or other car-
diovascular disease), gastrointestinal (GI) bleeding and
other. RESULTS: The 18,704 patients with stroke (48%
male) tended to be elderly (mean age 70.5 years). Nearly
two-thirds died during follow-up. At least 1 hospitaliza-
tion occurred in 13,952 (72.7%), a hazard of 36.2/100
person years and those hospitalized had 3.9 admissions
on average. Atherothrombotic causes were most frequent
(82.4%), the majority were stroke and TIA (53.2%), but
length of stay was longest for GI bleeds (mean 17.1 days
vs 16.1 for atherothrombotic disease). The admission
rates due to atherothrombotic disease were 3 times higher
in the month following stroke than after the ﬁrst year;
and higher with age greater than 65 years (hazard ratio
1.8, 95% CI 1.69–1.83), diabetes (1.7, 1.62–1.86), 
atrial ﬁbrillation (2.1, 1.96–2.30), hypertension (1.8
1.65–1.86), heart failure (2.1, 1.97–2.21) and prior
atherothrombotic events (1.2, 1.17–1.32). Atherothrom-
botic hospitalizations accrue costs between $442 per
patient per month in the ﬁrst month to $39 per patient
per month after 5 years. CONCLUSIONS: Patients 
surviving a stroke are frequently readmitted, mostly for
atherothrombotic problems, and these events accrue 
substantial costs, especially early on in the course 
post-stroke.
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AN INVESTIGATION OF THE CARE NEEDS
AFTER ACUTE ISCHEMIC STROKE: AN
ANALYSIS OF THE DATA COLLECTED IN 
THE ERLANGEN STROKE PROJECT
Ward AJ1, Payne KA2, Caro J1, Heuschmann PL3,
Kolominsky-Rabas P3
1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Montreal, QC, Canada; 3University of Erlangen,
Erlangen, Germany
OBJECTIVE: To determine the functional outcome, loca-
tion of care and economic consequences three months 
following hospitalization for ﬁrst ischemic stroke.
METHODS: As part of the Erlangen Stroke Project
(ESPro), information was collected on patients diagnosed
as having a stroke between April 1994 and March 1996.
Barthel Index (BI), Functional Independence Measure
(FIM) and location of care were determined three months
after the stroke. A subset of eight items from the FIM was
used to deﬁne patients as independent or dependent on
caregivers. BI scores three months after the stroke were
divided into three categories low (0–55), medium (60–90)
and high (95–100). Data collected about health and social
services used by these patients were combined with esti-
mates of costs for these services in Germany. Costs were
estimated in 2000 DM (1 = $ 0.53 USD, €0.51), undis-
counted. RESULTS: Information was recorded on 379
patients, half of whom had not fully recovered at 3
months (27% medium BI, 24% in low category). The
majority (79%) was residing in the community, 43%
remained dependent but 61% of them still returned to the
community. Cumulative costs of care over 3 months for
institutionalized patients with high BI were DM35, 100,
and with medium BI DM55,000; about 1.5 fold those of
patients in the same category residing in the community.
Costs for patients with low BI were higher whether in 
the community (DM51,600) or in institutional care
(DM53,400). CONCLUSION: Many patients were left
with a level of disability that required a substantial
amount of support from caregivers. In Germany, location
of care has an impact on the economic consequences at
higher levels of BI only.
